India rejects Bayer Nexavar CL appeal
This article was originally published in Scrip
Executive Summary
India's apex court recently dismissed Bayer's plea in the high profile Nexavar (sorafenib tosylate) compulsory licensing litigation, but the case hearing appears yet again to have touched upon the delicate issue of R&D spends along the way.